Actively Recruiting
An Innovative CFD-based Dosimetry and Pre-treatment Planning Platform to Support Personalized Transarterial Therapies for Liver Cancer
Led by University Hospital, Ghent · Updated on 2026-01-02
80
Participants Needed
1
Research Sites
66 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Ghent
Lead Sponsor
U
University Ghent
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research focuses on hepatocellular carcinoma (HCC), a primary form of liver cancer, and evaluates a new approach to improve treatment planning for transarterial radioembolization (TARE). TARE is a minimally invasive therapy where radioactive microspheres are delivered into the liver's blood vessels to target tumors. Despite its use, treatment outcomes vary due to complex liver blood flow and unpredictable microsphere distribution. The goal is to develop a personalized, patient-specific pre-treatment planning platform using computational models to better predict and optimize treatment outcomes. The study involves creating 3D digital models of each patient's liver arterial tree based on clinical imaging like CT, MRI, PET, SPECT, or DSA. These models use computational fluid dynamics (CFD) and radiation dosimetry simulations to study how treatment parameters affect the distribution of microspheres and radiation dose. The clinical part includes collecting retrospective and prospective imaging and treatment data from patients undergoing TARE without altering their treatment, aiming to build and validate these models. Participants provide imaging and treatment data which researchers use to analyze blood flow, microsphere transport, and radiation dose distribution. The study measures the accuracy of the CFD models, identifies key treatment parameters, and quantifies uncertainty in radiation dose to tumors and healthy liver tissue over four years. This data collection involves no additional risk or changes to clinical care, and the insights gained may support future personalized and safer TARE planning. The overall study period extends until the end of 2030.
CONDITIONS
Brief Title
An Innovative CFD-based Dosimetry and Pre-treatment Planning Platform to Support Personalized Transarterial Therapies for Liver Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Radiologically diagnosed with hepatocellular carcinoma (HCC), eligible for or undergoing treatment.
- Treated or planned to be treated using transarterial radioembolization (TARE) with radioactive microspheres.
- Pre-treatment medical imaging of hepatic arterial vasculature available for TARE planning (e.g., CT, MRI, PET, SPECT, DSA) to develop patient-specific 3D models.
You will not qualify if you...
- Undergoing TARE without adequate medical imaging of hepatic vasculature.
- No available pre- or post-treatment imaging data for analysis.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Treatment duration varies according to clinical care
Participants undergo transarterial radioembolization (TARE) as part of their routine clinical care. Imaging data from this treatment is collected for analysis without altering the clinical workflow.
Visits occur as part of routine treatment
Duration - Up to 4 years
Participants' imaging and treatment data are collected retrospectively and prospectively for up to 4 years to develop and validate 3D models and analyze treatment parameters.
Data collected during routine clinical visits
Trial Site Locations
Total: 1 location
1
University Hospital Ghent
Ghent, Belgium, 9000
Actively Recruiting
Research Team
E
Elisabeth Dhondt, Dr.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here